Skip to content

Exercise and Severe Depression: Clinical and Biological Analysis

Exercise and Severe Depression: Clinical and Biological Analysis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01899716
Enrollment
50
Registered
2013-07-15
Start date
2008-01-31
Completion date
2012-12-31
Last updated
2013-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Severe Depression, Quality of life, Exercise, BDNF, TBARS

Brief summary

The study aimed to evaluate the use of exercise as a complementary strategy to treat severe major depression in inpatients. Hypothesis: Exercise can be used as a safe and efficacious complimentary strategy in severe depressed inpatients.

Interventions

OTHERExercise

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Major Depressive Disorder according to M.I.N.I (DSM-IV) criteria American Psychiatry Association(1994) * score of 25 or more on Hamilton-17 * not being involved in other physical activity programs during the hospitalization * aged between 18 and 60 years * being able to read, understand, and provide written informed consent

Exclusion criteria

* have three or more cardiovascular risk factors according to Physical Activity Readiness Questionnaire (PAR-Q) * are unable to exercise due other clinical condition * have diagnosis of Schizophrenia, Bipolar disorder or current use of alcohol or other drugs according to M.I.N.I DSM-IV criteria American Psychiatry Association(1994) * if they are taking beta-blocking medications

Design outcomes

Primary

MeasureTime frameDescription
Depressive symptoms2 weeks of hospitalization (14 days)Hamilton 17 for depression

Secondary

MeasureTime frameDescription
Brain-Derived Neurotrophic Factor(BDNF)Baseline, after 2 weeks of hospitalization and at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks)
Quality of LifeBaseline, after 2 weeks of hospitalization and at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks)WHOQOL-BREF
Thiobarbituric acid reactive substances(TBARS)Baseline, after 2 weeks of hospitalization and at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks)
Depressive symptoms at discharge (participants will be followed for the duration of hospital stay, an expected average of 3 weeks)DischargeHamilton Scores at discharge

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026